These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39428978)

  • 21. Gut Microbiota and Sinusoidal Vasoregulation in MASLD: A Portal Perspective.
    Baffy G; Portincasa P
    Metabolites; 2024 Jun; 14(6):. PubMed ID: 38921459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetically predicted metabolites mediate the association between immune cells and metabolic dysfunction-associated steatotic liver disease: a mendelian randomization study.
    Ye D; Wang J; Shi J; Ma Y; Chen J; Hu X; Bao Z
    Lipids Health Dis; 2024 Aug; 23(1):249. PubMed ID: 39148061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period.
    Mori K; Tanaka M; Sato T; Akiyama Y; Endo K; Ogawa T; Suzuki T; Aida H; Kawaharata W; Nakata K; Hosaka I; Umetsu A; Hanawa N; Furuhashi M
    Hepatol Res; 2024 Aug; ():. PubMed ID: 39110552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiological Study on the Interaction between the
    Sato S; Iino C; Sasada T; Soma G; Furusawa K; Yoshida K; Sawada K; Mikami T; Nakaji S; Sakuraba H; Fukuda S
    Genes (Basel); 2024 Sep; 15(9):. PubMed ID: 39336763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut microbiota-derived metabolites as central regulators in metabolic disorders.
    Agus A; Clément K; Sokol H
    Gut; 2021 Jun; 70(6):1174-1182. PubMed ID: 33272977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation.
    Min BH; Devi S; Kwon GH; Gupta H; Jeong JJ; Sharma SP; Won SM; Oh KK; Yoon SJ; Park HJ; Eom JA; Jeong MK; Hyun JY; Stalin N; Park TS; Choi J; Lee DY; Han SH; Kim DJ; Suk KT
    Gut Microbes; 2024; 16(1):2307568. PubMed ID: 38299316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interventions for non-alcoholic liver disease: a gut microbial metabolites perspective.
    Guo J; Shi CX; Zhang QQ; Deng W; Zhang LY; Chen Q; Zhang DM; Gong ZJ
    Therap Adv Gastroenterol; 2022; 15():17562848221138676. PubMed ID: 36506748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis.
    Gurun M; Brennan P; Handjiev S; Khatib A; Leith D; Dillon JF; Byrne CJ
    PLoS One; 2024; 19(4):e0299507. PubMed ID: 38625981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bariatric-induced microbiome changes alter MASLD development in association with changes in the innate immune system.
    Shera S; Katzka W; Yang JC; Chang C; Arias-Jayo N; Lagishetty V; Balioukova A; Chen Y; Dutson E; Li Z; Mayer EA; Pisegna JR; Sanmiguel C; Pawar S; Zhang D; Leitman M; Hernandez L; Jacobs JP; Dong TS
    Front Microbiol; 2024; 15():1407555. PubMed ID: 39184030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
    Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
    Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of cholecystectomy on the gut-liver axis and metabolic disorders.
    Amaral Raposo M; Sousa Oliveira E; Dos Santos A; Guadagnini D; El Mourabit H; Housset C; Lemoinne S; Abdalla Saad MJ
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102370. PubMed ID: 38729564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gut-microbiota derived bioactive metabolites and their functions in host physiology.
    Debnath N; Kumar R; Kumar A; Mehta PK; Yadav AK
    Biotechnol Genet Eng Rev; 2021 Oct; 37(2):105-153. PubMed ID: 34678130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS.
    Perlin CM; Longo L; Thoen RU; Uribe-Cruz C; Álvares-DA-Silva MR
    Arq Gastroenterol; 2024; 61():e23100. PubMed ID: 38511793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut macrobiotic and its metabolic pathways modulate cardiovascular disease.
    Zhu J; Lyu J; Zhao R; Liu G; Wang S
    Front Microbiol; 2023; 14():1272479. PubMed ID: 37822750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease.
    Pan Z; Derbala M; AlNaamani K; Ghazinian H; Fan JG; Eslam M
    Ann Hepatol; 2024; 29(5):101512. PubMed ID: 38710473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic.
    Sato A; Oomori Y; Nakano R; Matsuura T
    Medicina (Kaunas); 2024 Aug; 60(8):. PubMed ID: 39202611
    [No Abstract]   [Full Text] [Related]  

  • 39. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations of the duodenal mucosal microbiome in patients with metabolic dysfunction-associated steatotic liver disease.
    Ren M; Pan H; Zhou X; Yu M; Ji F
    Sci Rep; 2024 Apr; 14(1):9124. PubMed ID: 38643212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.